BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31620934)

  • 1. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
    Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
    Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
    Loi S; Michiels S; Lambrechts D; Fumagalli D; Claes B; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Piccart MJ; Joensuu H; Sotiriou C
    J Natl Cancer Inst; 2013 Jul; 105(13):960-7. PubMed ID: 23739063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metastatic axillary lymph node ratio for Chinese breast cancer patients.
    Wu SG; He ZY; Li Q; Sun JY; Li FY; Lin Q; Lin HX; Guan XX
    PLoS One; 2013; 8(4):e61410. PubMed ID: 23626682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance).
    Boughey JC; Ballman KV; McCall LM; Mittendorf EA; Symmans WF; Julian TB; Byrd D; Hunt KK
    Ann Surg; 2017 Oct; 266(4):667-676. PubMed ID: 28657941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.
    Tomiguchi M; Yamamoto Y; Yamamoto-Ibusuki M; Goto-Yamaguchi L; Fujiki Y; Fujiwara S; Sueta A; Hayashi M; Takeshita T; Inao T; Iwase H
    Cancer Sci; 2016 Apr; 107(4):491-8. PubMed ID: 26801869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study.
    Li FY; Wu SG; Zhou J; Sun JY; Lin Q; Lin HX; Guan XX; He ZY
    PLoS One; 2014; 9(2):e87264. PubMed ID: 24498305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
    Abdel-Fatah TMA; Agarwal D; Liu DX; Russell R; Rueda OM; Liu K; Xu B; Moseley PM; Green AR; Pockley AG; Rees RC; Caldas C; Ellis IO; Ball GR; Chan SYT
    Lancet Oncol; 2016 Jul; 17(7):1004-1018. PubMed ID: 27312051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
    Zurrida S; Bagnardi V; Curigliano G; Mastropasqua MG; Orecchia R; Disalvatore D; Greco M; Cataliotti L; D'Aiuto G; Talakhadze N; Goldhirsch A; Viale G
    Eur J Cancer; 2013 Oct; 49(15):3083-92. PubMed ID: 23777741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
    Falck AK; Fernö M; Bendahl PO; Rydén L
    World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAP3K1 expression is associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer.
    Kuo SH; Wei MF; Lee YH; Lin JC; Yang WC; Yang SY; Huang CS
    Cell Oncol (Dordr); 2023 Oct; 46(5):1213-1234. PubMed ID: 37166744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
    Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
    Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
    Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
    Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.
    Chen H; Singh RR; Lu X; Huo L; Yao H; Aldape K; Abraham R; Virani S; Mehrotra M; Mishra BM; Bousamra A; Albarracin C; Wu Y; Roy-Chowdhuri S; Kanagal-Shamanna R; Routbort MJ; Medeiros LJ; Patel KP; Broaddus R; Sahin A; Luthra R
    Oncotarget; 2017 Feb; 8(7):10845-10857. PubMed ID: 28125801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
    Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
    BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.